Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [5]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN357734 - Provider product page
- Provider
- antibodies-online
- Product name
- anti-Promyelocytic Leukemia (PML) (Sumoylation Site) antibody
- Antibody type
- Polyclonal
- Description
- Protein G Chromatography, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS.
- Reactivity
- Human
- Host
- Rabbit
- Epitope
- Sumoylation Site
- Vial size
- 0.4 mL
- Storage
- Store the antibody undiluted at 2-8°C for one month or (in aliquots) at-20°C for longer.
- Handling
- Avoid repeated freezing and thawing.
Submitted references ZIP kinase triggers apoptosis from nuclear PML oncogenic domains.
Leukemia-associated translocation products able to activate RAS modify PML and render cells sensitive to arsenic-induced apoptosis.
High frequency of alternative splicing of human genes participating in the HIV-1 life cycle: a model using TSG101, betaTrCP, PPIA, INI1, NAF1, and PML.
The promyelocytic leukemia protein protects p53 from Mdm2-mediated inhibition and degradation.
PML is required for homeodomain-interacting protein kinase 2 (HIPK2)-mediated p53 phosphorylation and cell cycle arrest but is dispensable for the formation of HIPK domains.
Kawai T, Akira S, Reed JC
Molecular and cellular biology 2003 Sep;23(17):6174-86
Molecular and cellular biology 2003 Sep;23(17):6174-86
Leukemia-associated translocation products able to activate RAS modify PML and render cells sensitive to arsenic-induced apoptosis.
Puccetti E, Beissert T, Güller S, Li JE, Hoelzer D, Ottmann OG, Ruthardt M
Oncogene 2003 Oct 9;22(44):6900-8
Oncogene 2003 Oct 9;22(44):6900-8
High frequency of alternative splicing of human genes participating in the HIV-1 life cycle: a model using TSG101, betaTrCP, PPIA, INI1, NAF1, and PML.
Favre M, Butticaz C, Stevenson B, Jongeneel CV, Telenti A
Journal of acquired immune deficiency syndromes (1999) 2003 Oct 1;34(2):127-33
Journal of acquired immune deficiency syndromes (1999) 2003 Oct 1;34(2):127-33
The promyelocytic leukemia protein protects p53 from Mdm2-mediated inhibition and degradation.
Louria-Hayon I, Grossman T, Sionov RV, Alsheich O, Pandolfi PP, Haupt Y
The Journal of biological chemistry 2003 Aug 29;278(35):33134-41
The Journal of biological chemistry 2003 Aug 29;278(35):33134-41
PML is required for homeodomain-interacting protein kinase 2 (HIPK2)-mediated p53 phosphorylation and cell cycle arrest but is dispensable for the formation of HIPK domains.
Möller A, Sirma H, Hofmann TG, Rueffer S, Klimczak E, Dröge W, Will H, Schmitz ML
Cancer research 2003 Aug 1;63(15):4310-4
Cancer research 2003 Aug 1;63(15):4310-4
No comments: Submit comment
No validations: Submit validation data